Urogen's Chief Medical Officer Insider Trade: 400K Sale Insights
A high-profile insider sale at UroGen Pharma raises questions about market signals and biotech risk. This article unp...
Deciding between broad market and sector funds depends on diversification needs and risk tolerance. This guide compares outcomes and helps you decide.
28,547 articlesA high-profile insider sale at UroGen Pharma raises questions about market signals and biotech risk. This article unp...
For investors seeking reliable, long-term growth in energy, midstream pipelines stand out. Here are three brilliant e...
A growing alliance between Alphabet and Anthropic could redefine how AI is trained and deployed. This piece breaks do...
Merck faces the challenge of expiring patents while pushing a robust pipeline and disciplined capital moves. This gui...
A U.S. electronics maker and a Chinese supplier are reshaping their supplier networks to weather tariff shocks and ge...
As SM Energy reports Q4 2025 results, investors gain a window into the company's production mix, costs, and capital p...
As AI reshapes how consumers discover and buy, CMOs are expanding beyond brand storytelling to lead growth, data, and...
Rumors swirl about a $1B annual AI deal behind Siri’s next leap. This article breaks down who benefits, how it change...
Negotiating an auto loan at the dealership isn’t just about the monthly payment. This guide shows you how to lock in ...
As Xometry heads into 2025 earnings, investors seek clarity on growth, margins, and execution. This guide provides ac...
Explore ibotta (ibta) 2025 earnings projections, including revenue drivers, user growth, and profitability timelines....
A major AI feature sparked controversy in the writing world. Grammarly paused its 'Expert Review' tool after authors ...